Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.2174/1389202918666170329110349 http://scihub22266oqcxt.onion/10.2174/1389202918666170329110349 C5635644!5635644!29081694     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Curr+Genomics 2017 ; 18 (5): 378-84 Nephropedia Template TP {{tp|p=29081694|t=2017. Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment |pdf=|usr=}}{{29081694}} gab.com Text Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment JO: Curr Genomics http://www.kidney.de/pget.php?&tw=1&pmid=29081694 #FOAvip Introduction:: Since the first fusion gene was discovered decades ago, a considerable number of fusion genes have been detected in leukemia. The majority of them are generated through chromosomal rearrangement or abnormal transcription. With the development of techniques, high-throughput sequencing method makes it possible to detect fusion genes systematically in multiple human cancers. Owing to their biological significance and tumor-specific expression, some of the fusion genes are attractive diagnostic tools and therapeutic targets. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 fusions have been widely used to treat CML. The combination of ATRA and ATO targeting PML-RARA fusions has proven to be effective in acute promyelocytic leukemia (APL). Moreover, therapy with high dose cytarabine (HDAC) has significantly improved the prognosis of core binding factor (CBF) acute myeloid leukemia (AML) patients. Therefore, studies on fusion genes may benefit patients with leukemia by providing more diagnostic markers and therapies in the future. Conclusion:: The presented review focuses on the history of fusion genes, mechanisms of formation, and treatments against specific fusion genes in leukemia. Twit Text FOAVip Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment ????Curr Genomics http://www.kidney.de/pget.php?&tw=1&pmid=29081694 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29081694 #FOAvip English Wikipedia <ref>{{Cite pmid|29081694}}</ref> Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment #MMPMID29081694 Wang Y; Wu N; Liu D; Jin Y Curr Genomics 2017[Oct]; 18 (5): 378-84 PMID29081694show ga Introduction:: Since the first fusion gene was discovered decades ago, a considerable number of fusion genes have been detected in leukemia. The majority of them are generated through chromosomal rearrangement or abnormal transcription. With the development of techniques, high-throughput sequencing method makes it possible to detect fusion genes systematically in multiple human cancers. Owing to their biological significance and tumor-specific expression, some of the fusion genes are attractive diagnostic tools and therapeutic targets. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 fusions have been widely used to treat CML. The combination of ATRA and ATO targeting PML-RARA fusions has proven to be effective in acute promyelocytic leukemia (APL). Moreover, therapy with high dose cytarabine (HDAC) has significantly improved the prognosis of core binding factor (CBF) acute myeloid leukemia (AML) patients. Therefore, studies on fusion genes may benefit patients with leukemia by providing more diagnostic markers and therapies in the future. Conclusion:: The presented review focuses on the history of fusion genes, mechanisms of formation, and treatments against specific fusion genes in leukemia. äRecurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis(epmc).pdf DeepDyve Pubget Overpricing